OPIANT PHARMACEUTICALS INC (OPNT)

US6837501039 - Common Stock

20.65  -0.12 (-0.58%)

After market: 20.75 +0.1 (+0.48%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OPNT. OPNT was compared to 198 industry peers in the Pharmaceuticals industry. OPNT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, OPNT is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

OPNT had negative earnings in the past year.
In the past year OPNT has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: OPNT reported negative net income in multiple years.
In multiple years OPNT reported negative operating cash flow during the last 5 years.

1.2 Ratios

OPNT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 82.70%, OPNT belongs to the top of the industry, outperforming 89.59% of the companies in the same industry.
In the last couple of years the Gross Margin of OPNT has declined.
The Profit Margin and Operating Margin are not available for OPNT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.2%
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

OPNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OPNT has been increased compared to 1 year ago.
OPNT has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.19, we must say that OPNT is in the distress zone and has some risk of bankruptcy.
OPNT has a Altman-Z score of -1.19. This is comparable to the rest of the industry: OPNT outperforms 46.61% of its industry peers.
OPNT has a Debt/Equity ratio of 0.60. This is a neutral value indicating OPNT is somewhat dependend on debt financing.
OPNT has a Debt to Equity ratio of 0.60. This is in the lower half of the industry: OPNT underperforms 67.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -1.19
ROIC/WACCN/A
WACC9%

2.3 Liquidity

OPNT has a Current Ratio of 5.48. This indicates that OPNT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.48, OPNT is in the better half of the industry, outperforming 61.09% of the companies in the same industry.
A Quick Ratio of 5.48 indicates that OPNT has no problem at all paying its short term obligations.
OPNT has a better Quick ratio (5.48) than 61.99% of its industry peers.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48

5

3. Growth

3.1 Past

OPNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13200.00%.
OPNT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.13%.
The Revenue has been growing by 37.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-442.86%
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y37%
Revenue growth Q2Q-98.94%

3.2 Future

The Earnings Per Share is expected to grow by 66.96% on average over the next years. This is a very strong growth
Based on estimates for the next years, OPNT will show a quite strong growth in Revenue. The Revenue will grow by 17.51% on average per year.
EPS Next Y-2455.56%
EPS Next 2Y-255.39%
EPS Next 3Y66.96%
EPS Next 5YN/A
Revenue Next Year-80.95%
Revenue Next 2Y-11.14%
Revenue Next 3Y17.51%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

OPNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPNT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as OPNT's earnings are expected to grow with 66.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-255.39%
EPS Next 3Y66.96%

0

5. Dividend

5.1 Amount

No dividends for OPNT!.
Industry RankSector Rank
Dividend Yield N/A

OPIANT PHARMACEUTICALS INC

NASDAQ:OPNT (3/1/2023, 7:00:03 PM)

After market: 20.75 +0.1 (+0.48%)

20.65

-0.12 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap108.80M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 82.7%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2455.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y